PHINMA University of Pangasinan

College of Health Sciences

Name of Student Nurse: DE GUZMAN CRISHA ANGEL Date: 3-9-2022

Level/block/group : 2-BSN-8 Hospital/Area: N/A Clinical Instructor: Mrs. Kharissa Ugaban

NAME OF DRUG MECHANISM OF ACTION CONTRAINDICATIONS SIDE EFFECTS ADVERSE EFFECTS NURSING RESPONSIBILITIES
GENERIC NAME

- overactive - pain at the injection - Xerostomia - Monitor Vital Signs

Atropine - blocks the effects of thyroid gland site
acetylcholine, including - blurred vision - Monitor for signs and
excess acetylcholine due to - myasthenia - dry mouth symptoms of intraocular
organophosphorus gravis, a - photophobia pressure
BRAND NAME poisoning skeletal muscle -blurred vision
disorder - Tachycardia - Ensure adequate
Atropen. - works through competitive hydration; provide
-sensitivity to light
inhibition of postganglionic - closed angle - flushing, and environmental control
acetylcholine receptors and glaucoma -confusion hot skin. (temperature) to prevent
CLASSIFICATION direct vagolytic action hyperpyrexia.
- high blood -headache - Constipation
>Anticholinergic pressure difficulty with - Have patient void before
-dizziness urination, and taking medication if
>Antispasmodic Agents. - coronary artery anhidrosis urinary retention is a
disease -rapid or irregular problem
heart rate -  Coma
- chronic heart - . Report rash; flushing;
failure -flushing, - Hypersensitivity eye pain; difficulty
INDICATION
> anti-sialagogue/anti- breathing; tremors, loss of
- asthma coordination; irregular
vagal effect
heartbeat, palpitations;
- hiatal hernia headache; abdominal
>organophosphate/
distention; hallucinations;
- ulcerative severe or persistent dry
muscarinic poisoning mouth; difficulty
colitis
swallowing; difficulty in
>bradycardia - toxic urination; constipation;
megacolon sensitivity to light.

DOSAGE & FREQUENCY

- can be
administered by
intravenous (IV),
subcutaneous,
intramuscular, or
endotracheal (ET)
methods

- For ET
administration,
dilute 1 mg to 2 mg
in 10 mL of sterile
water or normal
saline before
administration.
- For pediatric ET,
double the usual IV
dose and dilute in 3
to 5 mL.

- Antisialagogue/anti-
vagal: 0.5 mg to 1
mg every 1 to 2
hours
- Organophosphate
or muscarinic
poisoning: 2 mg to
3 mg every 20 to
30 minutes (may
require doses up to
20 mg, titrate to
effect for secretion
control)
- Bradycardia: 1 mg
every 3 to 5
minutes (3 mg
max), repeat until
obtaining desired
 heart rate, most
effective for sinus
and AV nodal
disease.
It depends on the
physician